GlassScriptPhysician profile
Ying-Chun Lo
NPI 1487032470
$17,253.34
in general payments reported to CMS, 2019-2025
6 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Clinical Pathology/Laboratory Medicine providers received nationally (typical 2025 total: $114).
See the full distribution for Clinical Pathology/Laboratory Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,680 · 2023: $3,517 · 2024: $772 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $1,414 · Food and Beverage: $653 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,488.00 |
| Travel and Lodging | $1,413.87 |
| Food and Beverage | $653.38 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,038.03 | 2024-2025 | |
| Genzyme Corporation | $2,017.22 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,680.00 | 2021 | |
| Chromacode, INC | $1,500.00 | 2023 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying-Chun Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.